We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Glucose in Hospitalized Patients Predicts Diabetes Risk

By LabMedica International staff writers
Posted on 03 Sep 2014
Print article
Image: The three year risk of type 2 diabetes by admission glucose. The solid line represents the estimate and the ribbon represents the 95% confidence intervals (Graph courtesy of the Public Library of Science).
Image: The three year risk of type 2 diabetes by admission glucose. The solid line represents the estimate and the ribbon represents the 95% confidence intervals (Graph courtesy of the Public Library of Science).
Blood glucose levels measured in hospitalized adults during acute illness can be used to predict the risk of developing type 2 diabetes over the following three years.

Many patients admitted to hospital because of an acute illness have hyperglycemia, an abnormally high blood glucose level which can be caused by the drugs that patients are taking for existing conditions or may be stress hyperglycemia.

Scientists at the University of Edinburgh (UK) carried out a retrospective cohort study on patients aged 30 years or older with an emergency admission to hospital between 2004 and 2008. They obtained measurements of blood glucose levels on admission for 86,634 patients who were admitted to a hospital for an acute illness and identified those patients who developed type 2 diabetes up to December 2011.

The investigators found that the overall three year risk of developing type 2 diabetes was 2.3%, with the risk of developing diabetes increased linearly with increasing blood glucose level at admission. The three year risk of type 2 diabetes was 1% for patients with a glucose level of less than 5 mmol/L (90 mg/dL) and increased to approximately 15% for patients with glucose of 15 mmol/L (270 mg/dL) or more. The team developed a risk calculator that uses the patient's age, sex, and admission blood glucose level to predict risk of developing diabetes over three years following hospital admission.

The scientists confirm that single measures using the WHO cut-points for diagnosing diabetes, which are not based upon studies that measured glucose in the emergency setting cannot be directly applied in acutely unwell patients with hyperglycemia. They found that 90% of patients with admission glucose of 11.1 mmol/L (200 mg/dL) were not diagnosed with diabetes within three years of discharge from the hospital.

The authors conclude that the three year risk of type 2 diabetes was less than 1% for patients with a glucose of less than or equal to 5 mmol/L and increased linearly to approximately 15% at 15 mmol/L, above which there was no further increase in risk. Mortality was also 1.5-fold higher in patients with glucose levels of 11.1 to 15 mmol/L compared to those with glucose levels less than 6.1 mmol/L. These findings can be used to inform individual patients of their long-term risk of type 2 diabetes and to offer lifestyle advice as appropriate. The study was published on August 19, 2014, in the journal Public Library of Science Medicine.

Related Links:

University of Edinburgh


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.